ArticleFrontiers in immunology2022

A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation.

Weston L Daniel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.